Your browser does not support the NLM PubReader view.

Go to this page to see a list of supporting browsers.

Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma

Article information

Korean J Intern Med. 2021;36(5):1260-1260
Publication date (electronic) : 2021 September 1
doi : https://doi.org/10.3904/kjim.2020.549.e1
Jae-Woo Jung1,*, Hae-Sim Park2,*, Choon-Sik Park3, Sang-Heon Cho4, Inseon S. Choi5, Hee-Bom Moon6, Soon Seog Kwon7, Ho Joo Yoon8, Jung Won Park9, Jong-Myung Lee10, Dong-Chull Choi11, Byoung Whui Choi1,12
1Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
2Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea
3Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
4Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
5Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea
6Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
7Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea
8Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
9Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
10Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea
11Division of Allergy, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
12Department of Internal Medicine, Chung-Ang University H.C.S. Hyundae Hospital, Namyangju, Korea

In the article cited above, there was an error in Figure 3B. A corrected version of Figure 3B is attached.

Figure 3.

Korean asthma control test (K-ACT) at week 0, 16, and 24. (A) Mean ± standard error of the mean K-ACT. (B) Asthma control levels. K-ACT was improved after omalizumab treatment, and the proportions of “partly controlled” and “controlled” on week 16 and week 24 were higher than those at week 0. ap < 0.001, bp < 0.005 compared to K-ACT at week 0.

We apologize for any inconvenience that this may have caused.

Article information Continued

Copyright © 2021 The Korean Association of Internal Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Figure 3.

Figure 3.

Korean asthma control test (K-ACT) at week 0, 16, and 24. (A) Mean ± standard error of the mean K-ACT. (B) Asthma control levels. K-ACT was improved after omalizumab treatment, and the proportions of “partly controlled” and “controlled” on week 16 and week 24 were higher than those at week 0. ap < 0.001, bp < 0.005 compared to K-ACT at week 0.